Dr James Davies

2025

• Bayliss, R. J. et al. 2025. An αvβ6 specific precision virotherapy expressing bispecific immune cell activators induces immune cell activation and mediates tumour cell death. Molecular Therapy Oncology 33 (3) 201017. (10.1016/j.omton.2025.201017)

2024

• Badder, L. et al. 2024. The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers 2 potent “in-tumour” chemotherapy to Pancreatic Ductal Adenocarcinoma. British Journal of Cancer 131 , pp.1694-1706. (10.1038/s41416-024-02869-3)
• Bliss, C. M. et al. 2024. A pseudotyped adenovirus serotype 5 vector with serotype 49 fiber knob is an effective vector for vaccine and gene therapy applications. Molecular Therapy - Methods and Clinical Development 32 (3) 101308. (10.1016/j.omtm.2024.101308)

2023

• Bates, E. A. et al. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15 (5) 1086. (10.3390/v15051086)

2022

• Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25 , pp.43-56. (10.1016/j.omto.2022.03.007)

2021

• Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163 (4), pp.389-398. (10.1111/imm.13323)
• Davies, J. A. et al. 2021. Efficient intravenous tumor targeting using the αvβ6 integrin-selective precision virotherapy Ad5NULL-A20. Viruses 13 (5) 864. (10.3390/v13050864)
• Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95 (4) e01849-20. (10.1128/JVI.01849-20)

2020

• Wongthida, P. et al., 2020. Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors. Neuro-Oncology 22 (12), pp.1757-1770. (10.1093/neuonc/noaa126)
• Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27 , pp.785-798. (10.1038/s41417-019-0156-0)
• Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
• Elasifer, H. et al. 2020. Downregulation of HLA-I by the molluscum contagiosum virus mc080 impacts NK-cell recognition and promotes CD8+ T-cell evasion. Journal of General Virology 101 , pp.863-872. (10.1099/jgv.0.001417)

2019

• Man, S. et al., 2019. Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer. Scientific Reports 9 12840. (10.1038/s41598-019-49150-9)
• Baker, A. et al. 2019. Human adenovirus type 26 uses sialic acid - bearing glycans as a primary cell entry receptor. Science Advances 5 (9) eaax3567. (10.1126/sciadv.aax3567)
• Baker, A. T. et al. 2019. Adenovirus serotype 26 utilises sialic acid bearing glycans as a primary cell entry receptor. bioRxiv (10.1101/580076)
• Baker, A. T. et al. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nature Communications 10 741. (10.1038/s41467-019-08599-y)
• Nobre, L. V. et al., 2019. Human cytomegalovirus interactome analysis identifies degradation hubs, domain associations and viral protein functions. eLife 8 e49894. (10.7554/eLife.49894)

2018

• Uusi-Kerttula, H. et al. 2018. Ad5NULL-A20 - a tropism-modified, αvβ6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clinical Cancer Research 24 (17), pp.4215-4224. (10.1158/1078-0432.CCR-18-1089)
• Hulin-Curtis, S. et al. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9 (41), pp.26328-26341. (10.18632/oncotarget.25242)
• Wang, E. C. Y. et al. 2018. Suppression of costimulation by human cytomegalovirus promotes evasion of cellular immune defenses. Proceedings of the National Academy of Sciences 115 (19), pp.4998-5003. (10.1073/pnas.1720950115)
• Man, Y. K. S. et al., 2018. The novel oncolytic adenoviral mutant Ad5-3Δ-A20T retargeted to αvβ6 integrins efficiently eliminates pancreatic cancer cells. Molecular Cancer Therapeutics 17 (2), pp.575-587. (10.1158/1535-7163.MCT-17-0671)

2016

• Uusi-Kerttula, H. et al. 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7 (19), pp.27926-27937. (10.18632/oncotarget.8545)

2015

• Uusi-Kerttula, H. et al. 2015. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses 7 (11), pp.6009-6042. (10.3390/v7112923)
• Uusi-Kerttula, H. et al. 2015. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fibre knob domain, and their evaluation as targeted cancer therapies. Human Gene Therapy 26 (5), pp.320-329. (10.1089/hum.2015.015)

2014

• Seirafian, S. et al. 2014. Human cytomegalovirus suppresses Fas expression and function. Journal of General Virology 95 (4), pp.933-939. (10.1099/vir.0.058313-0)

2012

• Davies, J. A. et al. 2012. von Willebrand factor: demographics of plasma protein level in a large blood donor cohort from South Wales in the United Kingdom [Letter]. Haemophilia 18 (3), pp.e79-e81. (10.1111/j.1365-2516.2012.02782.x)
• Fielding, C. A. et al. 2012. A novel human cytomegalovirus gene function targets the natural killer cell activating ligand MICA for lysosomal degradation [Abstract]. Immunology 137 (S1), pp.154. (10.1111/imm.12001)

2011

• Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41 (9), pp.2741-2752. (10.1002/eji.201041350)

2010

• Stanton, R. J. et al. 2010. Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. Journal of Clinical Investigation 120 (9), pp.3191-3208. (10.1172/JCI42955)
• Prod'homme, V. et al. 2010. Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. Journal of General Virology 91 (8), pp.2034-2039. (10.1099/vir.0.021931-0)

2009

• Raby, A. et al. 2009. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. The Journal of Immunology 183 (1), pp.506-517. (10.4049/jimmunol.0802909)

2007

• Davies, J. A. and Bowen, D. J. 2007. The association between the L1565 variant of von Willebrand factor and susceptibility to proteolysis by ADAMTS13. Haematologica 92 (2), pp.240-243. (10.3324/haematol.10633)
• Davies, J. A. et al. 2007. von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. Journal of Thrombosis and Haemostatis 6 (1), pp.97-103. (10.1111/j.1538-7836.2007.02809.x)

2006

• Davies, J. A. et al. 2006. The effect of von Willebrand factor Y/C1584 on in vivo protein level and function, and interaction with ABO blood group. Blood 109 (7), pp.2840-2846. (10.1182/blood-2006-07-035105)